{
  "extraction_metadata": {
    "timestamp": "2025-09-05T09:35:22.092039",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 3,
    "total_picos": 40
  },
  "picos_by_country": {
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] for sotorasib vs 13.2% [95% CI: 8.6, 19.2] for docetaxel), duration of response (DoR), disease control rate, progression-free survival (PFS; median 15.24 months [14.85; 17.31] for sotorasib vs 6.87 [5.42; 12.52] months for docetaxel; HR 0.66 [95% CI: 0.51, 0.86], p=0.002; improvement at 12-month progression assessment: 24.8% vs 10.1%), overall survival (OS; median 10.6 months [95% CI: 8.9, 14.9] for sotorasib vs 11.3 months [95% CI: 9.0, 14.0] for docetaxel; HR 1.01 [95% CI: 0.77, 1.33], p=0.53; indirect comparison: HR 0.611 [95% CI: 0.451, 0.829], median OS extension of 7.2 months), time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (delayed with sotorasib; HR 0.694), quality of life (overall health status/quality of life stable with sotorasib, deterioration with docetaxel; change in mean squared minimums from baseline to week 12: 6.93 [95% CI: 3.66, 10.19]), time to deterioration of physical functioning, safety (adverse event rate; assessed by CTCAE v5.0; incidence of Grade 3-4 serious adverse events and fatalities higher in sotorasib group), discontinuations due to adverse events, dropout rate, mortality-related toxicity"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel + nintedanib",
          "Outcomes": "objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] for sotorasib vs 13.2% [95% CI: 8.6, 19.2] for docetaxel), duration of response (DoR), disease control rate, progression-free survival (PFS; median 15.24 months [14.85; 17.31] for sotorasib vs 6.87 [5.42; 12.52] months for docetaxel; HR 0.66 [95% CI: 0.51, 0.86], p=0.002; improvement at 12-month progression assessment: 24.8% vs 10.1%), overall survival (OS; median 10.6 months [95% CI: 8.9, 14.9] for sotorasib vs 11.3 months [95% CI: 9.0, 14.0] for docetaxel; HR 1.01 [95% CI: 0.77, 1.33], p=0.53; indirect comparison: HR 0.611 [95% CI: 0.451, 0.829], median OS extension of 7.2 months), time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (delayed with sotorasib; HR 0.694), quality of life (overall health status/quality of life stable with sotorasib, deterioration with docetaxel; change in mean squared minimums from baseline to week 12: 6.93 [95% CI: 3.66, 10.19]), time to deterioration of physical functioning, safety (adverse event rate; assessed by CTCAE v5.0; incidence of Grade 3-4 serious adverse events and fatalities higher in sotorasib group), discontinuations due to adverse events, dropout rate, mortality-related toxicity"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] for sotorasib vs 13.2% [95% CI: 8.6, 19.2] for docetaxel), duration of response (DoR), disease control rate, progression-free survival (PFS; median 15.24 months [14.85; 17.31] for sotorasib vs 6.87 [5.42; 12.52] months for docetaxel; HR 0.66 [95% CI: 0.51, 0.86], p=0.002; improvement at 12-month progression assessment: 24.8% vs 10.1%), overall survival (OS; median 10.6 months [95% CI: 8.9, 14.9] for sotorasib vs 11.3 months [95% CI: 9.0, 14.0] for docetaxel; HR 1.01 [95% CI: 0.77, 1.33], p=0.53; indirect comparison: HR 0.611 [95% CI: 0.451, 0.829], median OS extension of 7.2 months), time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (delayed with sotorasib; HR 0.694), quality of life (overall health status/quality of life stable with sotorasib, deterioration with docetaxel; change in mean squared minimums from baseline to week 12: 6.93 [95% CI: 3.66, 10.19]), time to deterioration of physical functioning, safety (adverse event rate; assessed by CTCAE v5.0; incidence of Grade 3-4 serious adverse events and fatalities higher in sotorasib group), discontinuations due to adverse events, dropout rate, mortality-related toxicity"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] for sotorasib vs 13.2% [95% CI: 8.6, 19.2] for docetaxel), duration of response (DoR), disease control rate, progression-free survival (PFS; median 15.24 months [14.85; 17.31] for sotorasib vs 6.87 [5.42; 12.52] months for docetaxel; HR 0.66 [95% CI: 0.51, 0.86], p=0.002; improvement at 12-month progression assessment: 24.8% vs 10.1%), overall survival (OS; median 10.6 months [95% CI: 8.9, 14.9] for sotorasib vs 11.3 months [95% CI: 9.0, 14.0] for docetaxel; HR 1.01 [95% CI: 0.77, 1.33], p=0.53; indirect comparison: HR 0.611 [95% CI: 0.451, 0.829], median OS extension of 7.2 months), time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (delayed with sotorasib; HR 0.694), quality of life (overall health status/quality of life stable with sotorasib, deterioration with docetaxel; change in mean squared minimums from baseline to week 12: 6.93 [95% CI: 3.66, 10.19]), time to deterioration of physical functioning, safety (adverse event rate; assessed by CTCAE v5.0; incidence of Grade 3-4 serious adverse events and fatalities higher in sotorasib group), discontinuations due to adverse events, dropout rate, mortality-related toxicity"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] for sotorasib vs 13.2% [95% CI: 8.6, 19.2] for docetaxel), duration of response (DoR), disease control rate, progression-free survival (PFS; median 15.24 months [14.85; 17.31] for sotorasib vs 6.87 [5.42; 12.52] months for docetaxel; HR 0.66 [95% CI: 0.51, 0.86], p=0.002; improvement at 12-month progression assessment: 24.8% vs 10.1%), overall survival (OS; median 10.6 months [95% CI: 8.9, 14.9] for sotorasib vs 11.3 months [95% CI: 9.0, 14.0] for docetaxel; HR 1.01 [95% CI: 0.77, 1.33], p=0.53; indirect comparison: HR 0.611 [95% CI: 0.451, 0.829], median OS extension of 7.2 months), time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (delayed with sotorasib; HR 0.694), quality of life (overall health status/quality of life stable with sotorasib, deterioration with docetaxel; change in mean squared minimums from baseline to week 12: 6.93 [95% CI: 3.66, 10.19]), time to deterioration of physical functioning, safety (adverse event rate; assessed by CTCAE v5.0; incidence of Grade 3-4 serious adverse events and fatalities higher in sotorasib group), discontinuations due to adverse events, dropout rate, mortality-related toxicity"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] for sotorasib vs 13.2% [95% CI: 8.6, 19.2] for docetaxel), duration of response (DoR), disease control rate, progression-free survival (PFS; median 15.24 months [14.85; 17.31] for sotorasib vs 6.87 [5.42; 12.52] months for docetaxel; HR 0.66 [95% CI: 0.51, 0.86], p=0.002; improvement at 12-month progression assessment: 24.8% vs 10.1%), overall survival (OS; median 10.6 months [95% CI: 8.9, 14.9] for sotorasib vs 11.3 months [95% CI: 9.0, 14.0] for docetaxel; HR 1.01 [95% CI: 0.77, 1.33], p=0.53; indirect comparison: HR 0.611 [95% CI: 0.451, 0.829], median OS extension of 7.2 months), time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (delayed with sotorasib; HR 0.694), quality of life (overall health status/quality of life stable with sotorasib, deterioration with docetaxel; change in mean squared minimums from baseline to week 12: 6.93 [95% CI: 3.66, 10.19]), time to deterioration of physical functioning, safety (adverse event rate; assessed by CTCAE v5.0; incidence of Grade 3-4 serious adverse events and fatalities higher in sotorasib group), discontinuations due to adverse events, dropout rate, mortality-related toxicity"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "platinum doublet",
          "Outcomes": "objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] for sotorasib vs 13.2% [95% CI: 8.6, 19.2] for docetaxel), duration of response (DoR), disease control rate, progression-free survival (PFS; median 15.24 months [14.85; 17.31] for sotorasib vs 6.87 [5.42; 12.52] months for docetaxel; HR 0.66 [95% CI: 0.51, 0.86], p=0.002; improvement at 12-month progression assessment: 24.8% vs 10.1%), overall survival (OS; median 10.6 months [95% CI: 8.9, 14.9] for sotorasib vs 11.3 months [95% CI: 9.0, 14.0] for docetaxel; HR 1.01 [95% CI: 0.77, 1.33], p=0.53; indirect comparison: HR 0.611 [95% CI: 0.451, 0.829], median OS extension of 7.2 months), time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (delayed with sotorasib; HR 0.694), quality of life (overall health status/quality of life stable with sotorasib, deterioration with docetaxel; change in mean squared minimums from baseline to week 12: 6.93 [95% CI: 3.66, 10.19]), time to deterioration of physical functioning, safety (adverse event rate; assessed by CTCAE v5.0; incidence of Grade 3-4 serious adverse events and fatalities higher in sotorasib group), discontinuations due to adverse events, dropout rate, mortality-related toxicity"
        },
        {
          "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy and tumours expressing PD-L1 with a TPS >=1%",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "objective response rate (ORR; primary endpoint; 28.1% [95% CI: 21.5, 35.4] for sotorasib vs 13.2% [95% CI: 8.6, 19.2] for docetaxel), duration of response (DoR), disease control rate, progression-free survival (PFS; median 15.24 months [14.85; 17.31] for sotorasib vs 6.87 [5.42; 12.52] months for docetaxel; HR 0.66 [95% CI: 0.51, 0.86], p=0.002; improvement at 12-month progression assessment: 24.8% vs 10.1%), overall survival (OS; median 10.6 months [95% CI: 8.9, 14.9] for sotorasib vs 11.3 months [95% CI: 9.0, 14.0] for docetaxel; HR 1.01 [95% CI: 0.77, 1.33], p=0.53; indirect comparison: HR 0.611 [95% CI: 0.451, 0.829], median OS extension of 7.2 months), time to progression, time to next treatment, event-free survival, time to deterioration of overall health status (delayed with sotorasib; HR 0.694), quality of life (overall health status/quality of life stable with sotorasib, deterioration with docetaxel; change in mean squared minimums from baseline to week 12: 6.93 [95% CI: 3.66, 10.19]), time to deterioration of physical functioning, safety (adverse event rate; assessed by CTCAE v5.0; incidence of Grade 3-4 serious adverse events and fatalities higher in sotorasib group), discontinuations due to adverse events, dropout rate, mortality-related toxicity"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10908
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy (only for patients with PD-L1 negative tumours)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy (only for patients with PD-L1 negative tumours and except in cases of predominantly squamous histology)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy (only for patients with PD-L1 expressing tumours (PD-L1 expression ≥ 1% of tumour cells))",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pembrolizumab",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        },
        {
          "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy (only for patients with PD-L1 negative tumours and adenocarcinoma histology)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS, defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review), overall survival (OS, defined as time from randomisation to death from any cause), symptomatology (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires), health status (assessed using EQ-5D VAS), health-related quality of life (assessed using EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, and PGI-C questionnaires; data not assessable), adverse events (AEs, total), serious adverse events (SAEs), severe adverse events, discontinuation due to AEs, specific AEs (including interstitial lung disease [severe AE], liver disorders [severe AEs], stomatitis, peripheral oedema, peripheral neuropathy, alopecia, blood and lymphatic system disorders, fatigue, fever, infections and infestations; with statistically significant differences for some specific AEs), risk of bias for endpoints (noted as high for OS, health status, discontinuation due to AEs, non-severe and non-serious specific AEs, and side effects endpoints due to study design and differential evaluation rates)"
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10591
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy (docetaxel or pemetrexed)",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel in combination with nintedanib",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "EGFR inhibitors in patients who have not received these medicines in the first line",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "osimertinib in patients previously treated with first or second generation EGFR blockers",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ALK inhibitors if ALK gene rearrangement",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunity (nivolumab or atezolizumab)",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "palliative radiotherapy",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "the second-line treatment of patients with NDRP with a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "symptomatic progression",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "Sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel (DOC)",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "Sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nintedanib in combination with docetaxel (NIN+DOC)",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "Sotorasib (SOT) was compared with docetaxel (DOC), nintedanib in combination with docetexel (NIN+DOC) and pemetrexed (XPM)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed (XPM)",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a KRas g12c mutation who have experienced disease progression after at least one line of previous use",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "other therapies that are currently publicly funded and are an alternative treatment available for the health problem",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "patients with NDRP and the KRAS mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "DOC",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasi",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "patients with NDRP with the KRASC G12 mutation, sotorasi is recommended for use in patients who have not responded to previous treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "other standard of care options",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "patients with non-small cell lung cancer (NDRP) with the presence of a p.G12C mutation in the KRAS gene (Kirsten rat viral oncogene homolog) after failure of at least one prior line of treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "patients with non-small cell lung cancer (NDRP) with the presence of a p.G12C mutation in the KRAS gene (Kirsten rat viral oncogene homolog) after failure of at least one prior line of treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nintedanib in combination with docetaxel (NIN+DOC)",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "patients with non-small cell lung cancer (NDRP) with the presence of a p.G12C mutation in the KRAS gene (Kirsten rat viral oncogene homolog) after failure of at least one prior line of treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "two-drug platinum-derived chemotherapy (P-CTH)",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "patients with non-small cell lung cancer (NDRP) with the presence of a p.G12C mutation in the KRAS gene (Kirsten rat viral oncogene homolog) after failure of at least one prior line of treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed (PMX)",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        },
        {
          "Population": "patients not previously treated with immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab or nivolumab",
          "Outcomes": "progression-free survival (PFS; median values reported in multiple studies, e.g., CodeBreaK 200: median 5.6 months [95% CI: 4.3; 7.8], Study 436: median 6.7 months [95% CI: 4.6; 8.3], Julve 2021: median 6.1 months [95% CI: 5.6; not reached]), overall survival (OS; e.g., median OS 12.5 months [95% CI: 10.0; not achieved]), overall response rate (ORR; e.g., SOT 28% vs DOC 13%, RR [95% CI] = 2.12 [1.35; 3.33]), disease control rate (DCR; e.g., DOC vs 83% RR compared to DOC group), quality of life (measured by EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, including time to deterioration and symptom-specific domains such as pain, cough, dyspnoea, chest pain, and general health), safety outcomes (adverse events [AEs], serious adverse events [SAEs], grade ≥3 adverse events, treatment-related adverse events leading to discontinuation, dose modification-related adverse reactions, treatment-associated AEs resulting in death, with specific risks for diarrhoea, increased ALT, increased AST, anaemia, headache, cough, shortness of breath, nausea, vomiting, constipation, abdominal pain, joint pain, back pain, fatigue, fever, increased asparaginase aminotransferase, increased alanine aminotransferase, alopecia, neutropenia, and peripheral neuropathy; treatment-related AEs reported in 65% of patients, grade ≥3 in 23%, discontinuation in 7%, dose modification in 26%, death in 1%), economic outcomes (incremental cost-utility ratio [ICUR], cost-utility analysis [CUA] from the public payer perspective, budget impact analysis), time to progression on subsequent therapy, and time to deterioration in quality of life."
        }
      ],
      "ChunksUsed": 44,
      "ContextTokens": 10268
    }
  }
}